



Express Mail No.: EV452773488US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application Srivastava et al. Confirmation No.: 1804  
of:  
Serial No.: 09/668,724 Art Unit: 1642  
  
Filed: September 22, 2000 Examiner: Christopher H. Yaen  
  
For: ALPHA (2) MACROGLOBULIN Attorney Docket No: 8449-128-999  
RECEPTOR AS A HEAT SHOCK PROTEIN  
RECEPTOR AND USES THEREOF

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. §1.56 to inform the U.S. Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the subject application which are or may be material to the patentability of any claim of the application, Attorneys for Applicants respectfully direct the Examiner's attention to the references C02-C07 listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references C02-C07 are enclosed.

Identification of the listed references is not to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants request that the Examiner review all the references identified on the attached revised PTO Form 1449, and that they be made of record in the file history of the above-identified application.


11/16/2004 LWONDIM1 00000001 503013 09668724  
01 FC:1806 180.00 DA

1551585-1

This Supplemental Information Disclosure Statement is being filed before a mailing of a final Office Action. As such, according to 37 CFR § 1.97(c), Applicants believe that a fee of \$180.00 is due in accordance with 37 CFR § 1.17(p). Please charge the required fee to Jones Day Deposit Account No. 503013. A duplicate copy of this sheet is enclosed for accounting purposes.


Respectfully submitted,

Date: November 8, 2004

  
Adriane M. Antler 32,605  
(Reg. No.)

**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, New York 10017-6702  
(212) 326-3939

Enclosures



Express Mail No. EV452773488US

Sheet 1 of 1

 <b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)		ATTY DOCKET NO.	APPLICATION NO.
		8449-128-999	09/668,724
		APPLICANT	
		Srivastava et al.	
		FILING DATE	GROUP
		September 22, 2000	1642

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

**OTHER REFERENCES** (*Including Author, Title, Date, Pertinent Pages, Etc.*)

C02	Binder and Srivastava, 2004, Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc. Natl. Acad. Sci. U.S.A. 101:6128-6133.	
C03	Binder <i>et al.</i> , 2002, Naturally formed artificially reconstituted non-covalent alpha 2-macroglobulin-peptide complexes elicit CD91-dependent cellular immunity. Cancer Immunity 2:16-24.	
C04	Basu <i>et al.</i> , 2001, CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14:303-313.	
C05	Herz and Strickland, 2001, LRP: a multifunctional scavenger and signaling receptor. J. Clin. Invest. 108:779-784.	
C06	Goto and Tanzi, 2002, The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation. J. Mol. Neurosci. 19:37-41.	
C07	The Merck Manual of Diagnosis and Therapy, 1999, Beers and Berkow eds., Merck Research Laboratories, Whitehouse Station N.J., pp. 1871 and 1872.	

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.